Warning Letter Roundup & Recap
This article was originally published in The Silver Sheet
Executive Summary
Zoll cited for QS and MDR violations; FDA instructs maker of drug-of-abuse kits to hire a consultant to audit the firm’s manufacturing and quality assurance systems; Ambco Electronics failed to fully investigate and document device failures. Eight quality-related warning letters were listed by FDA from Sept. 12 through Oct. 14.
You may also be interested in...
Court Revives Zoll Product Safety Suit Following Earlier Premption Ruling
The Eleventh Circuit Court of Appeals reversed a lower court's decision that US FDA regulations pre-empted a product liability suit against Zoll Medical. The suit was filed by the son of a woman who allegedly died after her Zoll LifeVest external defibrillator malfunctioned.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.